Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter B Gilbert

Showing results (51-60 of 337) with videos related to

Pageof 34
Sort By:
Biometrics|September 21, 2006
A comparison of eight methods for the dual-endpoint evaluation of efficacy in a proof-of-concept HIV vaccine trialDevan V Mehrotra, Xiaoming Li, Peter B Gilbert
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|March 11, 2021
Evaluating the Long-term Efficacy of Coronavirus Disease 2019 (COVID-19) VaccinesDan-Yu Lin, Donglin Zeng, Peter B Gilbert
Annals of Statistics|October 20, 2009
PROPORTIONAL HAZARDS MODELS WITH CONTINUOUS MARKSYanqing Sun, Peter B Gilbert, Ian W McKeague
Statistica Sinica|August 17, 2013
Quantile Regression for Competing Risks Data with Missing Cause of FailureYanqing Sun, Huixia Judy Wang, Peter B Gilbert
Statistics in Medicine|July 18, 2019
Assessing pharmacokinetic marker correlates of outcome, with application to antibody prevention efficacy trialsPeter B Gilbert, Yuanyuan Zhang, Erika Rudnicki, et al.
Biostatistics (Oxford, England)|July 2, 2013
Case-only method for cause-specific hazards models with application to assessing differential vaccine efficacy by viral and host geneticsJames Y Dai, Shuying S Li, Peter B Gilbert
Journal of the American Statistical Association|November 5, 2013
Sensitivity Analysis of Per-Protocol Time-to-Event Treatment Efficacy in Randomized Clinical TrialsPeter B Gilbert, Bryan E Shepherd, Michael G Hudgens
Biostatistics (Oxford, England)|September 22, 2016
Statistical methods for down-selection of treatment regimens based on multiple endpoints, with application to HIV vaccine trialsYing Huang, Peter B Gilbert, Rong Fu, et al.
Lifetime Data Analysis|April 11, 2020
Analysis of the time-varying Cox model for the cause-specific hazard functions with missing causesFei Heng, Yanqing Sun, Seunggeun Hyun, et al.
Statistics in Medicine|October 30, 2014
Comparing and combining biomarkers as principal surrogates for time-to-event clinical endpointsErin E Gabriel, Michael C Sachs, Peter B Gilbert
Pageof 34

Showing results (51-60 of 337) with videos related to

Sort By:
Pageof 34
Biometrics|September 21, 2006
A comparison of eight methods for the dual-endpoint evaluation of efficacy in a proof-of-concept HIV vaccine trialDevan V Mehrotra, Xiaoming Li, Peter B Gilbert
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|March 11, 2021
Evaluating the Long-term Efficacy of Coronavirus Disease 2019 (COVID-19) VaccinesDan-Yu Lin, Donglin Zeng, Peter B Gilbert
Annals of Statistics|October 20, 2009
PROPORTIONAL HAZARDS MODELS WITH CONTINUOUS MARKSYanqing Sun, Peter B Gilbert, Ian W McKeague
Statistica Sinica|August 17, 2013
Quantile Regression for Competing Risks Data with Missing Cause of FailureYanqing Sun, Huixia Judy Wang, Peter B Gilbert
Statistics in Medicine|July 18, 2019
Assessing pharmacokinetic marker correlates of outcome, with application to antibody prevention efficacy trialsPeter B Gilbert, Yuanyuan Zhang, Erika Rudnicki, et al.
Biostatistics (Oxford, England)|July 2, 2013
Case-only method for cause-specific hazards models with application to assessing differential vaccine efficacy by viral and host geneticsJames Y Dai, Shuying S Li, Peter B Gilbert
Journal of the American Statistical Association|November 5, 2013
Sensitivity Analysis of Per-Protocol Time-to-Event Treatment Efficacy in Randomized Clinical TrialsPeter B Gilbert, Bryan E Shepherd, Michael G Hudgens
Biostatistics (Oxford, England)|September 22, 2016
Statistical methods for down-selection of treatment regimens based on multiple endpoints, with application to HIV vaccine trialsYing Huang, Peter B Gilbert, Rong Fu, et al.
Lifetime Data Analysis|April 11, 2020
Analysis of the time-varying Cox model for the cause-specific hazard functions with missing causesFei Heng, Yanqing Sun, Seunggeun Hyun, et al.
Statistics in Medicine|October 30, 2014
Comparing and combining biomarkers as principal surrogates for time-to-event clinical endpointsErin E Gabriel, Michael C Sachs, Peter B Gilbert
Pageof 34